Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review

Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease

(2018) Éva Szökő et al.   JOURNAL OF NEURAL TRANSMISSION

Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease

(2018) Muhammed Khairujjaman Mazumder et al.   MEDICAL HYPOTHESES

Motor fluctuations and levodopa-induced dyskinesias in dopa-responsive dystonia

(2018) Venkata Sunil Bendi et al.   PARKINSONISM & RELATED DISORDERS

Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China

(2018) Zhenxin Zhang et al.   Translational Neurodegeneration

Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan

(2018) Nobutaka Hattori et al.   PARKINSONISM & RELATED DISORDERS

Prostaglandin E1 plus methylcobalamin combination therapy versus prostaglandin E1 monotherapy for patients with diabetic peripheral neuropathy

(2018) De-Qi Jiang et al.   MEDICINE

Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study

(2017) Emanuele Cereda et al.   JOURNAL OF NEUROLOGY

Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia

(2017) Laura L. Frakey et al.   JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES

Rasagiline for dysexecutive symptoms during wearing-off in Parkinson’s disease: a pilot study

(2017) Domiziana Rinaldi et al.   NEUROLOGICAL SCIENCES

Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial

(2016) Daniel Weintraub et al.   MOVEMENT DISORDERS

Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease

(2015) Daphne Robakis et al.   CNS DRUGS

A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients

(2015) P. Barone et al.   EUROPEAN JOURNAL OF NEUROLOGY

Rasagiline for the treatment of Parkinson’s disease: an update

(2015) Fabrizio Stocchi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease

(2015) Thien Thien Lim et al.   MOVEMENT DISORDERS

Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease

(2015) Robert A. Hauser et al.   JAMA Neurology

Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease

(2014) Paul L. McCormack   CNS DRUGS

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease

(2014) Robert A. Hauser et al.   MOVEMENT DISORDERS

Monoamine Oxidase B Prompts Mitochondrial and Cardiac Dysfunction in Pressure Overloaded Hearts

(2013) Nina Kaludercic et al.   ANTIOXIDANTS & REDOX SIGNALING

Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial

(2013) Lina Zhang et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials

(2013) Lawrence W. Elmer   PARKINSONISM & RELATED DISORDERS

Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease

(2011) F. Stocchi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Safety of rasagiline for the treatment of Parkinson's disease

(2011) Santiago Perez-Lloret et al.   Expert Opinion On Drug Safety

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study

(2011) Hasmet A. Hanagasi et al.   MOVEMENT DISORDERS

Increased Oxidative Damage and Decreased Antioxidant Function in Aging Human Substantia Nigra Compared to Striatum: Implications for Parkinson’s Disease

(2011) C. Venkateshappa et al.   NEUROCHEMICAL RESEARCH

TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease

(2009) Ken Ikeda et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain

(2009) Orly Weinreb et al.   JOURNAL OF NEURAL TRANSMISSION

L-dopa therapy for Parkinson's disease: Past, present, and future

(2009) Toshiharu Nagatsu et al.   PARKINSONISM & RELATED DISORDERS

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE